NICE Clinical Guideline 103

Delirium: Diagnosis, prevention and management

The recommendations from NICE cover:
  • Risk factor assessment
  • Indicators of delirium:
    • at presentation
    • daily observations
  • Interventions to prevent delirium
  • Diagnosis (specialist clinical assessment)
  • Treating delirium, including:
    • initial management
    • distressed people.
Web address: www.nice.org.uk/guidance/CG103
NICE Clinical Guideline 104

Metastatic malignant disease of unknown primary origin

The recommendations from NICE cover:
  • Organisation of services and support
  • Diagnosis, including
    • initial diagnostic phase
    • second diagnostic phase—special investigations
    • investigation of specific clinical presentations
  • Factors influencing management decisions
  • Managing specific presentations
  • Systemic treatment.
Web address: www.nice.org.uk/guidance/CG104
NICE Clinical Guideline 105

Motor neurone disease: The use of non-invasive ventilation in the management of motor neurone disease

The recommendations from NICE cover:
  • Information and support needs of patients with motor neurone disease (MND) and their families and carers
  • Identification and assessment of respiratory impairment in patients with MND, including:
    • symptoms and signs
    • respiratory function tests
  • Non-invasive ventilation for treatment of respiratory impairment in patients with MND.
Web address: www.nice.org.uk/guidance/CG105

NICE Technology Appraisal 191

Capecitabine for the treatment of advanced gastric cancer

Summary:
  • Capecitabine in combination with a platinum-based regimen is recommended for the first-line treatment of inoperable advanced gastric cancer
  • Offer capecitabine if:
    • patients have not had treatment for advanced stomach cancer before and
    • their cancer cannot be removed with an operation.
Web address: www.nice.org.uk/guidance/TA191
NICE Technology Appraisal 192

Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

Summary:
  • Gefitinib is recommended as an option for the first-line treatment of people with locally advanced or metastatic non-small-cell lung cancer if:
    • the patient tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and
    • the manufacturer provides gefitinib at a fixed price agreed under the patient access scheme.
Web address: www.nice.org.uk/guidance/TA192
NICE Technology Appraisal 193

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

Summary:
  • Rituximab, in combination with fludarabine and cyclophosphamide, is recommended as a possible treatment for people with relapsed or refractory chronic lymphocytic leukaemia except when:
    • the patient has had rituximab before, unless
      • in the context of a clinical trial, in combination with chemotherapy other than fludarabine and cyclophosphamide or
      • in the context of a clinical trial, at a dose lower than the dose currently licensed for chronic lymphocytic leukaemia
    • the condition is refractory to fludarabine (i.e. it did not respond to fludarabine before or it worsened within 6 months of treatment).
Web address: www.nice.org.uk/guidance/TA193
NICE Public Health Guidance 27

Dietary interventions and physical activity interventions for weight management before, during and after pregnancy

The recommendations from NICE cover:
  • Preparing for pregnancy (i.e. provide advice for women with a body mass index [BMI] of ?30 kg/m2)
  • Pregnant women
  • Supporting women after childbirth
  • Women with a BMI of ?30 kg/m2 who have recently given birth
  • Community based services
  • Professional skills.
Web address: www.nice.org.uk/guidance/PH27